Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 1818 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page


    Advanced search

    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Email Alert *
    Add to My List *
* Registration required (free)  


 Article Access Statistics
    PDF Downloaded673    
    Comments [Add]    

Recommend this journal


 Table of Contents    
Year : 2011  |  Volume : 53  |  Issue : 2  |  Page : 180-182
Antidepressants: From MAOIs to SSRIs and more

1 Department of Neurology, Nimhans, India
2 M. S. Ramaiah Medical College, Bangalore, Karnataka, India
3 Department of Psychiatry, Psychotherapy and Psychosomatic Medicine, Ruhr-Univeristy, Bochum, Germany
4 Department of Neuroscience, University of Alberta, Edmonton, Alberta, Canada
5 Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada; Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, Detroit, Michigan, USA

Click here for correspondence address and email

Date of Web Publication30-Jun-2011

How to cite this article:
Ramachandraih CT, Subramanyam N, Bar KJ, Baker G, Yeragani VK. Antidepressants: From MAOIs to SSRIs and more. Indian J Psychiatry 2011;53:180-2

How to cite this URL:
Ramachandraih CT, Subramanyam N, Bar KJ, Baker G, Yeragani VK. Antidepressants: From MAOIs to SSRIs and more. Indian J Psychiatry [serial online] 2011 [cited 2021 Aug 3];53:180-2. Available from:

The era of antidepressants started with isoniazid, an antitubercular agent, which was accidentally found to have euphoric effects in patients with tuberculosis who were receiving this drug. The mood elevating property of the drug, considered to be a side effect, became the primary effect in depression and heralded the synthesis of generations of newer antidepressants. It also shifted the focus of psychiatrists from psychodynamic processes to a biological basis of the illness. [1]

Isoniazid belongs to a group of hydrazine compounds, which were synthesized by Fischer in the 1870's. Isonicotinyl hydrazine (isoniazid) was synthesized by Meyer and Malley at Prague from these hydrazine compounds. Forty years later it was re-synthesized by another group of scientists. By chance, it was found to be an effective antitubercular agent. In 1952, Zeller discovered that iproniazid, another hydrazine derivative, inhibited monoamine oxidase (MAO) enzyme, so named by a group of scientists led by Blaschko and Richter in 1937. The enzyme caused the oxidation of adrenaline, a monoamine and was inhibited by ephedrine. However, Mary Hare had observed similar results in 1928 with an enzyme, tyramine oxidase, which later was found to be MAO. The MAO enzyme acts on a number of endogenous and exogenous amines (serotonin, catecholamines, tyramine, beta-phenylethylamine, benzylamine). In the year 1952, Selikoff and Robidzek observed that iproniazid had greater psychostimulatory effects than isoniazid in patients with and without tuberculosis. Subsequent studies by Smith, Kamman, and del Pino found similar stimulatory effects. The effects were described as mood elevating. The patients showed increased vigor and appetite, weight gain, improved sleep, and sociability. In some cases, it caused psychomotor agitation, hypersexuality and psychoses, behavior described as "dancing in the hall". Lurie, a private psychiatrist, coined the term "antidepressant" for the psychostimulatory effects of isoniazid in depressed patients. Until then various terms such as "thymeretics" and "psychic energizers" were used to describe these effects. Kline, Loomer, and Saunders found a correlation between the effects of the antitubercular agents and their inhibitory action on MAO and used iproniazid for the first time on a group of patients with depression. They recorded significant improvement in 70% of the patients. Later studies showed that its MAO-inhibiting property increased serotonin levels in the brain similar to the effects seen with 5-hydroxytrytophan, a precursor of serotonin, which crosses the blood-brain barrier. This was also substantiated by the reversal of reserpine-induced depression by iproniazid, as reserpine depletes biogenic amines. These studies showed promising results in depression through clinical and biochemical observations, Iproniazid was launched as an antitubercular agent because of disagreements among psychiatrists and also due to its hepato and nephrotoxicity. The drug and some other hydrazine derivatives were later taken off of the market. [2],[3]

The above findings paved the way to the develolpment of the first class of exclusive MAO inhibitors such as isocarboxazid, tranylcypramine, phenelzine, mebanazine, nialamide, pheniprazine, and etryptamine (an indole derivative). In the meantime, the enzyme MAO was reported by Johnston, in 1968, to exist in two isomeric forms. MAO-A was found in the small intestine and MAO-B was extracted from rat brain. MAO-A deaminated adrenaline, noradrenaline, and serotonin, whereas MAO-B acted on benzylamine and β-phenylethylamine. Dopamine and tyramine were the substrates for both of the isomeric forms. The classical MAO inhibitors such as tranylcypramine and phenelzine inhibited both the isoenzymes. Tranylcypramine, a derivative of cyclopropylamine, was first used in 1959 as an antidepressant, and soon MAO inhibitors became frequently prescribed antidepressants. Later on, there were several reports of these drugs being associated with hepatotoxicity and death due to hypertensive crises and intracranial hemorrhages. The hypertensive crisis was particularly seen with the concomitant administration of sympathomimetics. This was first described by Blackwell and he called it the "cheese effect", as it was associated with the consumption of certain types of cheese. This rise in the blood pressure was because of irreversible inhibition of MAO-A (published as the first psychiatric pearl in IJP). The necessity to avoid this side effect resulted in the synthesis of selective inhibitors such as l-deprenyl (selective, irreversible inhibitor of MAO-B) and moclobemide (selective, reversible inhibitor of MAO-A) to avoid the fatal hypertensive crisis. l-Deprenyl was not a particularly effective antidepressant, but proved useful in treatment of Parkinson's disease; however, recently it has been used as an antidepressant given transdermally [4] . Currently, MAO inhibitors are not first choice antidepressants, and are usually used only when there is intolerance or lack of response to the newer drugs, refractory depression or when ECT is contraindicated. [1]

The tricyclic antidepressants are derived from antihistaminic compounds, which were the predecessors of phenothiazines, the discovery of which was a revolution in the history of biological psychiatry. In 1948, Halfinger and Schindler, working at Geigy, synthesized 42 products from iminodibenzyl. Kuhn headed the experiments on G-22150. After the initial animal and human studies, he found no sedative effects but observed that the drug had some positive effects on psychiatric patients. In 1952, Deniker and Delay had a breakthrough with chlorpromazine as an effective antipsychotic. Kuhn wanted to test the efficacy of G-22150 as an antipsychotic but was given G-22355 (imipramine) instead due to G-22150's intolerable side effects. In 1956, Kuhn used imipramine, which had a similar side chain as chlorpromazine, on patients with depressive psychosis and witnessed a remarkable improvement within a few weeks. Extended studies for a year showed that the drug was very effective and the finding was published in a Swiss journal in 1957. Once again the product had to face skepticism, like chlorpromazine. During those times, the hypothesis of depression stemming from intrapsychic conflicts was firmly held, and hence it was believed that the antidepressants could only result in symptomatic relief. Geigy introduced imipramine onto the market in 1957 and named it "Tofranil". The drug continued to be a success in patients with depression and Kuhn started to give lectures on recommendations regarding the indications, dosage and duration of treatment. This was followed by two publications in the American Journal of Psychiatry. Kuhn's observations were confirmed by other studies, including those of Lehmann who agreed with Kuhn about the significance of imipramine in depressive illnesses. Hence, Roland Kuhn is considered one of the pioneers in biological psychiatry and psychopharmacology. In 1961, a second tricyclic antidepressant, amitriptyline, was synthesized and Frank Ayd Jr showed that this compound had similar effects to imipramine; amitriptyline was launched as "Elavil". Series of tricyclics followed, desipramine, nortriptyline, trimipramine, and doxepin. Clomipramine, synthesized in 1958, was also found to be effective in obsessive compulsive disorder after a series of studies in 1967 and the drug was launched in 1975. The first tetracyclic antidepressant, maprotiline, was developed by Wilhelm and Schmidt in 1967 and clinical studies conducted by Kuhn found it to be an effective antidepressant. Mianserin, another tetracyclic, is presently being used in depression in the elderly and for pain modulation. [2]

The comparable effects of both MAO inhibitors and tricyclics led to the hypothesis by Sulser and Axelrod in 1960 that despite different mechanisms, the final mode of action was common, i.e., increased availability of free serotonin and catecholamines in the brain. [3] is also worth mentioning here the effectiveness of these agents in other medical illnesses such as various anxiety disorders, migraine, chronic pain, irritable bowel syndrome, and chronic urticaria.

The above discoveries led to a new era in the development of psychotropics, i.e., the era of rational drug development, in which the molecules are designed to act on a particular site, receptors or enzymes or reuptake pumps. This approach avoids the undesirable side effects of serendipitously discovered drugs, which often have actions on multiple sites such as cholinergic, alpha-adrenergic, histaminic, and fast sodium ion channels. Dr. Arvid Carlsson was the first one to develop the antidepressant compound, zimeldine, which was the first selective serotonin re-uptake inhibitor (SSRI). The precursor of this drug was brompheniramine. Here, one should note that he also did substantial work on the synthesis and metabolism of 5-hydroxytryptamine (serotonin) in the central nervous system. [4],[5] Zimelidine produced a serious neurological side effect, Guillian-Barre syndrome, in a few patients and thus was withdrawn from the market. [6]

Five new SSRI antidepressants were designed by five different pharmaceutical companies [7] . They were fluoxetine, fluvoxamine, paroxetine, sertraline, and citalopram (which is now also marketed as S-enantiomer). These drugs act on serotonergic neurons, thus inherently causing side effects related to serotonin function namely sexual dysfunction, nausea, incoordination, tremors, akathisia, and the serotonin syndrome, which can be fatal. The ever increasing knowledge of pathophysiological mechanisms of depression has led to the synthesis of other drugs, which affect both serotonin and norepinephrine reuptake (SNRIs: venlafaxine, duloxetine). These drugs inhibit norepinephrine and dopamine reuptake (bupropion and its metabolites), and antagonize serotonin-2 receptor (trazodone) or presynaptic α2 adrenergic receptors (mirtazapine) in addition to inhibiting serotonin reuptake. Currently, the indications for many Antidepressant drugs have broadened to a wide variety of psychiatric illnesses such as panic disorder, obsessive compulsive disorder, generalized anxiety disorder, phobic disorders, and premature ejaculation. [8]

At present, SSRIs and SNRIs are the first drugs of choice for most psychiatrists to treat depressive illness but the antidepressants also have an undeniable place in the management of depression. Sometimes the combination of SSRIs with tricyclic antidepressants is of great value in the management of treatment-resistant depression.

Knowledge of brain function and of the neurobiology of depression has increased enormously in recent years and has increased awareness that the biogenic amines cannot be considered in isolation with regard to the etiology and pharmacotherapy of depression. Exciting new targets, which are being investigated with regard to antidepressant drug development, include the amino acids GABA and glutamate, neuroactive steroids, corticotrophin releasing factor (CRF), and substance P, cytokines, neurotrophic factors, and melatonin receptors. Some atypical antipsychotics now appear to be useful antidepressants when combined with standard antidepressants or even on their own. These new developments in antidepressant research have been reviewed recently. [9],[10],[11]

   References Top

1.Lopez-Munoz F, Alamo C, Juckel G, Assion HJ. Half a century of antidepressants: On clinical introduction of monoamine oxidase inhibitors, tricyclics and tetracyclics. Part 1: Monoamine oxidase inhibitors. J Clin Pharmacol 2007;27:555-9.  Back to cited text no. 1
2.Fangmann P, Assion HJ, Juckel G, Gonzalez CA, Lopez-Munoz F. Half a century of antidepressants: On clinical introduction of monoamine oxidase inhibitors, tricyclics and tetracyclics. Part 2: Tricyclics and tetracyclics. J Clin Pharmacol 2008;28:1-4.  Back to cited text no. 2
3.Pletscher A. The Discovery of antidepressants: A winding path. Experientia 1991;47:4-8.  Back to cited text no. 3
4.Culpepper L, Kovalick LJ. A review of the literature on the selegiline transdermal system: An effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression. Primary Care Companion. J Clin Psychiatry 2008;10:25-30.   Back to cited text no. 4
5.Carlsson A, Bedard P, Lindqvist M, Magnusson T. The influence of nerve-impulse flow on the synthesis and metabolism of 5-hydroxytryptamine in the central nervous system. Biochem Soc Symp 1972:17-32.  Back to cited text no. 5
6.Fagius J, Osterman PO, Siden A, Wiholm BE. Guillain-Barre syndrome following zimeldine treatment. J Neurol Neurosurg Psychiatry 1985;48:65-9.  Back to cited text no. 6
7.Butler SG, Meegan MJ. Recent developments in the design of antidepressant therapies: Targeting the serotonin transporter. Curr Med Chem 2008;15:1737-61.  Back to cited text no. 7
8.Thase ME. Are SNRIs more effective than SSRIs? A Review of the current state of the controversy. Psychopharmacol Bull 2008;41:58-85.  Back to cited text no. 8
9.Holtzheimer PE 3rd, Nemeroff CB. Advances in the treatment of depression. NeuroRx 2006;3:42-56.   Back to cited text no. 9
10.Berton O, Nestler EJ. New approaches to antidepressant drug discovery: Beyond monoamines. Nat Rev Neurosci 2006;7:137-51.   Back to cited text no. 10
11.Baker GB, Mitchell ND. Chemical mechanisms of depression. In: Begley TP. Wiley Encyclopedia of Chemical Biology. New York, NY: John Wiley and Sons, Inc.; 2008.0  Back to cited text no. 11

Correspondence Address:
Vikram K Yeragani
Flat No 103, Embassy Orchid, 8 Main, 6 Cross, Sadashiva Nagar, Bangalore - 560 080, Karnataka, India

Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0019-5545.82567

Rights and Permissions